Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Year: 2014
Type: article
Abstract: Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicated for most patients. New monoclonal antibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mammalian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.
Source: Blood
Authors: Meletios A. Dimopoulos, Efstathios Kastritis, Roger G. Owen, Robert A. Kyle, Ola Landgren, Enrica Morra, Xavier Leleu, Ramón García-Sanz, Nikhil Munshi, Kenneth C. Anderson, Evangelos Terpos, Irene M. Ghobrial, Pierre Morel, David Maloney, Mathias Rummel, Véronique Leblond, Ranjana H. Advani, Morie A. Gertz, Charalampia Kyriakou, Sheeba K. Thomas, Bart Barlogie, Stephanie A. Gregory, Eva Kimby, Giampaolo Merlini, Steven P. Treon
Institutions: National and Kapodistrian University of Athens, Mayo Clinic, National Cancer Institute, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Instituto de Investigación Biomédica de Salamanca, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Centre Hospitalier de Lens, Fred Hutch Cancer Center, Justus-Liebig-Universität Gießen, Assistance Publique – Hôpitaux de Paris, Université Pierre-et-Marie-Curie, Stanford Cancer Institute, The Royal Free Hospital, The University of Texas MD Anderson Cancer Center, University of Arkansas for Medical Sciences, Rush University Medical Center, Karolinska University Hospital, University of Pavia, Policlinico San Matteo Fondazione
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2160940401